Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) and Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Institutional and Insider Ownership
31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Amneal Pharmaceuticals and Quoin Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Amneal Pharmaceuticals | $2.93 billion | 1.56 | -$116.89 million | $0.02 | 726.00 |
| Quoin Pharmaceuticals | N/A | N/A | -$8.96 million | ($31.73) | -0.23 |
Quoin Pharmaceuticals has lower revenue, but higher earnings than Amneal Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and price targets for Amneal Pharmaceuticals and Quoin Pharmaceuticals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Amneal Pharmaceuticals | 0 | 1 | 4 | 0 | 2.80 |
| Quoin Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Amneal Pharmaceuticals presently has a consensus target price of $13.80, suggesting a potential downside of 4.96%. Given Amneal Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Amneal Pharmaceuticals is more favorable than Quoin Pharmaceuticals.
Volatility and Risk
Amneal Pharmaceuticals has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Profitability
This table compares Amneal Pharmaceuticals and Quoin Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Amneal Pharmaceuticals | 0.20% | -185.60% | 6.20% |
| Quoin Pharmaceuticals | N/A | -334.41% | -125.15% |
Summary
Amneal Pharmaceuticals beats Quoin Pharmaceuticals on 11 of the 13 factors compared between the two stocks.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
